Michelle Garcia-Outeda
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).
Journal: Antimicrobial agents and chemotherapy
Published: February 19, 2026
Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants.
Journal: Antimicrobial agents and chemotherapy
Published: December 22, 2025
Enterococcus thailandicus: Genomic evidence of a potential new player in enterococcal virulence and antimicrobial resistance.
Journal: New microbes and new infections
Published: September 09, 2025
Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: May 27, 2025
The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii.
Journal: Antimicrobial agents and chemotherapy
Published: May 20, 2025
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors.
Journal: Antimicrobial agents and chemotherapy
Published: January 10, 2025
Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.
Journal: Antimicrobial agents and chemotherapy
Published: November 15, 2024
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
Journal: Antimicrobial agents and chemotherapy
Published: October 09, 2024
Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 16, 2024
Corrigendum to "Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions" [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150].
Journal: International journal of antimicrobial agents
Published: July 09, 2024
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa.
Journal: The Journal of antimicrobial chemotherapy
Published: February 23, 2024
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Journal: International journal of antimicrobial agents
Published: January 03, 2024
Last Updated: 09/26/2026